CNP-103 not checked
COUR Pharmaceutical Development Company, Inc.
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes and 2 more
- Main trialPhase 1/2
- “This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (275 days).”In the company’s words, NCT06783309 on ClinicalTrials.gov
- Other names
- Treatment
Other drugs for Type 1 Diabetes Mellitus
- TirzepatideEli Lilly · Phase 3
- Insulin icodecNovo Nordisk · Phase 3
- CadisegliatinvTv Therapeutics · Phase 3
- Stem Cell Educator therapyYong Zhao, MD, PhD · Phase 3
- VX-017Vertex Pharmaceuticals · Phase 3
- VX-880Vertex Pharmaceuticals · Phase 3
Coming up1
- Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovCompletion date moved: 2026-12 to 2027-08 · ClinicalTrials.gov NCT06783309
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Aug 2027 | CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026